|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Overall, no association was observed between TP53 gene codon72 polymorphism and prostate cancer risk (Arg vs Pro: odds ratio [OR] = 1.12, 95% confidence interval [CI] = 0.98-1.30; ArgArg vs ProPro: OR = 1.26, 95% CI = 0.90-1.75; ProPro vs ArgArg+ ArgPro: OR = 1.17, 95% CI = 0.86-1.57; ArgPro+ ProPro vs ArgArg: OR = 1.21, 95% CI = 0.97-1.51).
|
31232967 |
2019 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Silencing of CD24 enhanced restoration of PRIMA-1-induced mutant p53 in endogenous TP53(P223L/V274F) DU145 cells and in PC3 cells transfected with TP53(R273H) CONCLUSIONS: In human prostate cancers, there is CD24-dependent inactivation of mutant p53.
|
26712693 |
2016 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, several questions regarding the determination of p53 alterations in prostate cancer, such as the poor correlation between immunohistochemistry and molecular genetic analysis, remain to be clarified.
|
10367371 |
1999 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude that alterations in p53 function are infrequent in clinically localized prostate cancers but are more common in advanced cancers.
|
8053489 |
1994 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Testing of prostate cancer biopsy specimens from metastatic sites for p53 protein accumulation and gene mutation may provide useful prognostic information and could influence the recommended course of treatment.
|
7692074 |
1993 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We investigated the potential prognostic roles of p53 (codon 72) and XRCC1 (codons 194, 280, and 399) polymorphisms in clinical localized prostate cancer after radical prostatectomy.
|
18006764 |
2007 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although p53 mutations in primary prostate cancer tissues are relatively infrequent, they occur at significant levels in metastatic disease.
|
9815823 |
1997 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here we use a sensitized, non-metastatic Pten/Trp53-mutant RapidCaP system for functional validation of human metastasis drivers in a much accelerated time frame of only 3-4months.
|
25592467 |
2015 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that TP53 and MDM2 polymorphisms play a role in PCa susceptibility in southern Chinese Han population.
|
20875869 |
2010 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
While for Asians, TP53 codon 72 polymorphism was unlikely to be a risk factor for prostate cancer.
|
19499352 |
2010 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Together these findings appear to explain, at least in part, why there has been a wide discrepancy in the reported detection frequency of p53 mutations in prostate cancer specimens.
|
7604888 |
1995 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
At stage T1, none of prostate cancers and 41.2% of bladder cancers contained mutant p53.
|
9072541 |
1997 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A significant association of codon 72 TP53 Pro/Pro genotype was observed with the risk of CaP (OR, 2.59, P=0.02) and BPH (OR, 6.27, P<0.001).
|
23168703 |
2012 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to assess the possible role of HPV in the development of prostate cancer (PCa) and investigate the distribution of the p53 codon 72 polymorphism in PCa in a Turkish population.
|
28124524 |
2017 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
|
26512780 |
2015 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the selective elimination of p53 mutant cells will likely have an impact in the treatment of prostate cancer.
|
15805289 |
2005 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate whether the TP53 codon 72 polymorphism and HPV infection are responsible for susceptibility to prostate cancer in Iranian men.
|
22825821 |
2012 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our study strongly supports the notion that KLF6 and TP53 mutations are not frequent events in prostate cancer.
|
19020536 |
2008 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PTEN deletions were present in 20.2% (458/2266) of prostate cancers, including 8.1% heterozygous and 12.1% homozygous deletions, and were linked to advanced tumor stage (P < 0.0001), high Gleason grade (P < 0.0001), presence of lymph node metastasis (P = 0.0002), hormone-refractory disease (P < 0.0001), presence of ERG gene fusion (P < 0.0001), and nuclear p53 accumulation (P < 0.0001).
|
22705054 |
2012 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found no association between p53 codon 72 polymorphism and prostate cancer risk.
|
22179964 |
2011 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study was undertaken to investigate the radiosensitizing effects of curcumin in p53 mutant prostate cancer cell line PC-3.
|
14985701 |
2004 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data suggest a high sensitivity of our immunohistochemistry approach and confirm the overall low frequency of p53 alterations in clinically localized prostate cancer.
|
18552821 |
2008 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we reported that miR-145 was silenced through DNA hypermethylation and p53 mutation status in laser capture microdissected (LCM) prostate cancer and matched adjacent normal tissues.
|
21349819 |
2011 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The gain of MYCN and AURKA oncogenes, along with the loss of tumor suppressor genes TP53 and RB1 are key genomic alterations associated with treatment-related neuroendocrine prostate cancer.
|
29396873 |
2018 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although ras and p53 gene mutations have been detected in some prostate cancers, the major genetic alterations involved in its carcinogenesis are not well understood.
|
8609698 |
1996 |